newsfilter
← Latest News
Business Wire·

Dicerna Announces Poster Presentations at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021 in November

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that two abstracts related to the Company's clinical development programs have been accepted for poste